Aquarius Surgical Technologies Inc.
21.7.2021 01:57:21 CEST | ACCESS Newswire | Press release
TORONTO, ON / ACCESSWIRE / July 20, 2021 / Aquarius Surgical Technologies Inc. (CSE:ASTI)(the "Company") announces an update to the Press Release issued on July 19, 2021, when it announced that there is an anticipated delay in filing Annual Financial Results for the year ended March 31, 2021, and that an Application was being made to the Ontario Securities Commission for a Management Cease Trade Order pursuant to National Policy 12-203.
The Company has been notified by the Ontario Securities Commission that a Management Cease Trade Order will not be issued, and that unless the Audited Annual Financial Statements, the Management's Discussion & Analysis and related CEO and CFO Certificates for the year ended March 31, 2021 (the "Annual Filings") are not filed by July 29, 2021 (the "Regulatory Filing Deadline"), then a Cease Trade Order will be issued.
While the Company anticipates that it will not be able to complete the filing of Annual Filings by the Regulatory Filing Deadline, it is continuing to work closely with its Auditors to complete the necessary review and assessments, with a view to filing the Annual Filings at the earliest opportunity.
If the Annual Filings cannot be completed before the Regulatory Filing Deadline, the Company will not be able to file of the Interim Unaudited Financial Statements, MD&A and the related CEO and CFO Certificates for the First Quarter, ended June 30, 2021 (the "Interim Filings"), which are due to be filed by August 30, 2021; the filing of the Interim Filings will thus be delayed until after the Annual Filings have been completed.
About Aquarius Surgical Technologies Inc.
Aquarius Surgical Technologies is an exclusive provider of innovative, minimally invasive medical laser systems and consumables for multiple medical disciplines, principally in the field of urology. Solutions also include clinical education, service, support and maintenance. ASTI is focused on increasing the availability of services for patients, enhancing the quality of patient care, improving operationally efficiencies and reducing total operational costs.
For more information, please contact:
Lorne MacFarlane, CFO lornemac@eastlink.ca
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: Aquarius Surgical Technologies Inc.
View source version on accesswire.com:
https://www.accesswire.com/656397/Aquarius-Provides-an-Update-on-the-Anticipated-Delay-in-Filing-of-Annual-Financial-Results-for-the-Year-Ended-March-31-2021
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Anew Climate Expands European Forest Carbon Portfolio Through Ten-Year Agreement with Sweden's EKEN1.10.2026 15:00:00 CEST | Press release
HOUSTON, TX / ACCESS Newswire / October 1, 2026 / Anew Climate (Anew), one of the world's largest developers and marketers of carbon credits, announced a ten-year agreement with EKEN Financing Value Added Forestry (EKEN) to bring Swedish improved forest management (IFM) credits to corporate buyers worldwide. The agreement extends Anew's European forest carbon portfolio, which it maintains alongside millions of acres of managed forestland across North America. Under the collaboration, Anew will serve as the exclusive commercialization partner for credits generated from projects developed by EKEN, handling purchaser engagements, structuring, and portfolio integration for corporate buyers in Europe and internationally. EKEN is preparing the project for development under VM0045, Verra's methodology for improved forest management using dynamic matched baselines from national forest inventories. While many conventional forest carbon baselines rest on a projection of what a landowner would hy
Karbon‑X (OTCQB:KARX) Reports Record Fiscal 2026 Revenue of $55.9 Million as Company Scales Global Carbon Market Operations1.10.2026 14:30:00 CEST | Press release
CALGARY, AB / ACCESS Newswire / October 1, 2026 / Karbon‑X Corp. (OTCQB:KARX) ("Karbon‑X" or the "Company"), a vertically integrated climate solutions company operating across global carbon markets, today reported financial and operational results for the fiscal year ended May 31, 2026, reflecting a significant increase in operating scale across its carbon credit trading and project development activities. Karbon‑X generated record fiscal 2026 revenue of $55.9 million, compared with $3.16 million in fiscal 2025, representing an increase of approximately 1,670% year over year. Gross profit was $0.86 million, compared with $0.80 million in the prior year. Fiscal 2026 results reflected a shift in revenue mix toward high-volume, lower-margin trading activity as Karbon‑X completed its first full year of large-scale carbon credit trading. "Fiscal 2026 moved Karbon-X into a new stage of commercial growth," said Chad Clovis, Chief Executive Officer of Karbon-X. "Revenue reached nearly eighteen
Surmodics Acquires Alta Biomed Business, Expanding Hemocompatible Surface Technology and Analytical Testing Capabilities1.10.2026 14:00:00 CEST | Press release
HORSHAM, PA / ACCESS Newswire / October 1, 2026 / Surmodics Inc., a leading provider of surface technologies and performance coatings for the medical device industry, today announced that it has acquired the business of Alta Biomed, a Carlsbad, California-based medical device coating and testing services company specializing in surface technologies for vascular and other medical devices. The acquisition is a strategic addition to Surmodics' growing portfolio of hemocompatible and biocompatible surface technologies. It brings Alta Biomed's proprietary PzF™ thin-film surface modification technology to Surmodics, adding an established anti-thrombotic, anti-inflammatory and pro-healing option that joins Surmodics' existing hemocompatible portfolio. "As medical device innovation advances in neuromodulation, brain-computer interfaces, neurovascular, structural heart, and venous and arterial technologies, engineers and scientists need a broader range of surface technology options to address i
PharmaNest and Mediar Therapeutics Collaborate to Quantify ECM and Fibrosis Remodeling in the EncompaSSc Phase 2 Trial of MTX-474 in Diffuse Cutaneous Systemic Sclerosis30.9.2026 19:00:00 CEST | Press release
PRINCETON, NJ / ACCESS Newswire / September 30, 2026 / PharmaNest, Inc. an AI-enabled digital pathology company specializing in the quantitative and spatial characterization of fibrosis and Mediar Therapeutics, Inc., a clinical-stage biotechnology company pioneering first-in-class therapies to halt and reverse fibrosis, today announced a collaboration to integrate advanced digital pathology into Mediar's ongoing EncompaSSc Phase 2 clinical trial of MTX-474 in patients with diffuse cutaneous systemic sclerosis (dcSSc). MTX-474 is a first-in-class human IgG1 monoclonal antibody designed to neutralize EphrinB2 signaling, a pathway implicated in myofibroblast activation, extracellular matrix (ECM) deposition and tissue remodeling known to drive fibrosis in SSc. The randomized, double-blind, placebo-controlled EncompaSSc Phase 2 study is evaluating the safety and efficacy of MTX-474 in patients with dcSSc. Under the collaboration, PharmaNest will apply its FibroNest™ AI-enabled digital path
Innodata Opens Motion-Capture AI Lab to Help Humanoids Move Like Humans30.9.2026 15:50:00 CEST | Press release
NEW YORK, NY / ACCESS Newswire / September 30, 2026 / Innodata Inc. (Nasdaq:INOD) today announced the opening of a new R&D laboratory that is designed to generate the data needed to train the next generation of human-like robots and independently validate the performance data that robots generate internally. Innodata developed the lab in collaboration with Vicon, a leader in motion capture who consulted on the lab design and continues to provide technical consulting. The New Jersey-based lab is equipped with high-precision, low-latency infrared optical tracking cameras that measure movement down to the sub-millimeter level-a degree of accuracy that methods such as wearable inertial measurement unit (IMU) sensors and single-camera (monocular) video analysis typically cannot match. The lab addresses an urgent need for high-quality training data for humanoids, industrial robots, and other forms of physical AI. While many other data providers infer 3D motion by analyzing 2D video, Innodata
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom